Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study

NCT02413736 is registered in ClinicalTrials.gov with Heikki Joensuu as lead sponsor.

NCT NCT02413736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02413736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study
Lead sponsor
Heikki Joensuu
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 31, 2015
Completion date
June 30, 2033
Enrollment
255 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma